HHS authorizes $81M in Zika vax funding after Congressional gridlock

Courtesy of Sarah Stierch

While U.S. lawmakers are out on summer vacation, the urgency to develop an effective Zika vaccine remains. And so HHS Secretary Sylvia Burwell has signed off on an $81 million fund allocation for federal agencies to continue research, though officials are stressing the amount is far shy of what is really needed.

In a letter to U.S. House of Representatives minority leader Nancy Pelosi, Burwell said $34 million would go to the NIH while BARDA would get $47 million “in order to ensure that neither is forced to delay their Zika vaccine work as the fiscal year closes.”

The NIAID, which has entered the clinic with a DNA-based Zika vaccine candidate, will use its money to prepare for a move into Phase II. At a press briefing, director Anthony Fauci said that Phase I is expected to wrap up at the end of this year, but that the NIAID needs nearly $200 million more for its work, according to Reuters. Burwell said NIH has three more candidates under development, but no resources to support them.

BARDA’s tranche will allow the agency to enter into contracts with private partners, but that agency will need another $342 million next year, Burwell said.

The move comes as local transmission has been documented in Florida and during the same week that the Obama administration officials declared a public health emergency in Puerto Rico, which has reported 10,690 Zika cases, according to Reuters.

In July, Congress left for a 7-week break without passing a Zika funding bill just as the spread further threatened areas in the U.S. In her letter, Burwell said “the lack of a clean, bipartisan Zika funding bill has left me no choice but to move forward with this action at this time."

- read Burwell's letter
- here's Reutersstory
- get more on Puerto Rico

Related Articles:
Congressional inaction will disrupt Zika vaccine R&D, officials say
GSK jumps into Zika vax hunt on heels of Sanofi's deal
Sanofi enlists for top Army hospital’s fight against Zika virus
Big Pharmas cautious on Zika vaccine development
Obama: Zika funding would hasten U.S. vaccine development
GSK relocates vaccine R&D to Maryland with new global center

Read more on

Suggested Articles

Despite having lost some of its novelty, AZ's Brilinta is touting bleeding data over aspirin that could be a big break in acute coronary syndrome.

More than a year after J&J and Bayer pulled the plug on Xarelto in patients after a rare valve replacement, the pair are still seeking answers.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.